8-K filing — Cytek Biosciences, Inc. (CTKB)
Filed: 2026-09-29 AccNo: 0001193125-26-407330 Size: 347 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Cytek Biosciences Q2 EPS $(0.09), Inline, Sales $48.140M Miss $48.610M Estimate
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.04) per share from the same period last year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cytek Biosciences Says Jury Finds In Cytek’s Favor On Three Of Four Asserted Patent Claims; To Challenge Remaining Finding; Jury Awarded Past Damages Consisting Of $20M In Lost Profits And $36M In Royalties
Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court
Cytek Biosciences Raises FY2026 Sales Guidance from $205.000M-$212.000M to $207.000M-$212.000M vs $208.767M Est
Cytek Biosciences (NASDAQ:CTKB) raises FY2026 sales outlook from $205.000 million-$212.000 million to $207.000 million-$212.000 million vs $208.767 million estimate.